查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372852

原位雜合技術市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、按應用、最終用戶、地區和競爭細分

In Situ Hybridization Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Product, By Technology, By Application, By End user, By Region and By Competition
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

原位雜合技術市場 2022 年估值為 15.3 億美元，預計到 2028 年將實現顯著成長，年複合成長率為 7.29%。如新冠肺炎 (COVID-19)。此外，對分子診斷工具不斷成長的需求，加上原位雜合技術技術的日益採用，將在未來幾年支撐市場的成長。

此外，人口中遺傳性疾病盛行率的激增有望成為預測期內成長的關鍵驅動力。同時，各個市場參與者為推動原位雜合技術技術所採取的策略性舉措，包括合作、收購和合併，預計將在整個預測期內對市場成長產生重大正面影響。

美國國家癌症研究所報告稱，2021 年美國新增癌症病例達 1,898,160 例，癌症相關死亡病例達 608,570 例，這一數字令人震驚。值得注意的是，世界衛生組織的資料強調，到2021 年9月，美國癌症患者的70%與癌症相關的死亡集中在低收入和中等收入國家。

市場概況
預測期 2024-2028
2022 年市場規模 15.3億美元
2028 年市場規模 23.4億美元
2023-2028 年年複合成長率 7.29%
成長最快的細分市場 醫院和診斷實驗室
最大的市場 北美洲

慢性病盛行率不斷上升

慢性疾病對全球原位雜合技術市場的發展軌跡有重大影響。癌症、自體免疫疾病和傳染病等疾病表現出細胞內遺傳畸變或突變的標誌，有助於透過原位雜合技術技術進行檢測和可視化。原位雜合技術的實用性在於其能夠識別和查明與這些疾病相關的特定核酸序列，從而實現及時診斷和精準治療。

分子生物學和遺傳學的進展

分子生物學的發展對全球原位雜合技術市場的擴張產生了重大影響。原位雜合技術位於分子生物學領域，是一種有助於精確檢測和定位細胞或組織內特定核酸序列的技術。分子生物學的最新技術進步顯著提高了原位雜合技術測定的敏感度、特異性和精確度。

探針設計和合成的進步顯著增強了原位雜合技術測定的特異性和靈敏度。例如，鎖核酸 (LNA) 探針代表了一項突破性發展，能夠以更高的特異性和靈敏度識別低豐度核酸標靶。同樣，標記和訊號放大技術的改進提高了原位雜合技術測定的信噪比，從而能夠辨別微弱訊號和低豐度標靶。

成像和顯微鏡技術的進步也促進了原位雜合技術市場的擴大。共焦顯微鏡和超解析度顯微鏡等先進的顯微鏡方法大大提高了原位雜合技術測定的空間解析度，從而促進了亞細胞結構和分子相互作用的可視化。

此外，當代分子生物學的成就為原位雜合技術的新應用鋪平了道路。例如，螢光原位雜合技術 (FISH) 已發展到可以同時檢測多個核酸標靶，從而能夠分析複雜的遺傳交互作用和基因表現模式。此外，RNA原位雜合技術技術的進步使得非編碼RNA的檢測成為可能，非編碼RNA是基因調控和疾病發生的關鍵參與者。

個人化醫療需求不斷成長

個人化醫療是推動全球原位雜合技術市場擴張的關鍵催化劑。這種醫療保健方法的重點是根據患者獨特的基因組成、生活方式和環境影響為其量身定做治療方案。原位雜合技術在這項範式中的關鍵作用在於它能夠發現與不同疾病相關的特定基因突變或生物標記物，使其成為個人化醫療開發的關鍵工具。

原位雜合技術譜中的螢光原位雜合技術 (FISH) 和顯色原位雜合技術 (CISH) 等技術在檢測與包括癌症在內的多種疾病相關的目標基因突變或改變方面脫穎而出。這些見解使醫生能夠為每位患者制定最佳治療途徑，提高治療效果，同時減輕不良副作用。

原位雜合技術的普遍作用延伸到伴隨診斷領域，其功能是識別最有可能從特定治療中受益的患者的測試。伴隨診斷可用於臨床試驗中的患者選擇、治療反應監測和劑量調整，從而提高患者治療效果並減少醫療支出。

原位雜合技術在個人化醫療中的作用軌跡有望在可預見的未來顯著擴展。這種推動力源自於遺傳訊息的不斷增加和對精準治療的需求不斷增加。創新原位雜合技術技術和檢測方法的同步開發將加速全球原位雜合技術市場的發展。

增加研究和開發活動

研究和開發工作對全球原位雜合技術市場的擴張產生了顯著的影響。作為一種不斷發展的技術，原位雜合技術的發展取決於新型測定方法和技術的不斷創造，這些方法和技術擴展了其應用範圍，同時提高了其測定的精密度、靈敏度、特異性和準確性。在原位雜合技術領域，研究和開發活動圍繞探針的改進、標記和訊號放大技術的最佳化以及成像和顯微鏡方法的進步。

例如，肽核酸（PNA）探針和鎖核酸（LNA）探針等創新探針技術的出現顯著提高了原位雜合技術測定的靈敏度和特異性。以酪醯胺訊號放大 (TSA) 為代表的標記和訊號放大技術的進步提高了這些檢測的訊號雜訊比，從而能夠辨別微弱訊號和低豐度標靶。同時，成像和顯微鏡技術的發展促進了原位雜合技術市場的成長軌跡。共焦顯微鏡和超解析度顯微鏡等高解析度顯微鏡模式顯著提高了原位雜合技術測定的空間解析度，促進了亞細胞結構和分子相互作用的可視化。

此外，研究和開發計劃的範圍涵蓋了原位雜合技術新應用的探索。一個值得注意的例子是該技術在研究非編碼 RNA 的分佈和表達模式的應用。由於非編碼 RNA 在基因調控和疾病進展中的關鍵作用，此特定途徑具有重要意義。

醫療保健支出增加

醫療保健支出是影響全球原位雜合技術市場擴張的關鍵決定因素。對原位雜合技術檢測和技術的需求激增本質上與一系列疾病（尤其是癌症）對精確可靠的診斷工具和療法的需求交織在一起。這種激增本質上與醫療保健支出的不斷增加有關，尤其是在已開發經濟體，大量投資用於研發活動和尖端醫療保健技術的採用。這種一致的推動力催生了新穎且具創造性的原位雜合技術技術和測定方法，其特點是更高的準確性、靈敏度、特異性和適用性。

此外，醫療保健支出與醫療保健服務的提供（包括診斷工具和治療）之間的連結是推動原位雜合技術市場成長的關鍵。醫療保健支出的增加支撐了包括醫院、診所和實驗室在內的醫療保健基礎設施的出現，從而增加了診斷工具（包括原位雜合技術檢測）的可用性和可近性。

同時，不斷升級的醫療支出模式刺激了個人化醫療的進步，這反過來又支持了原位雜合技術市場的擴張。個人化醫療強調根據患者的基因組成、生活方式和環境影響進行客製化治療。值得注意的是，原位雜合技術在個人化醫療中的關鍵作用因其識別與不同疾病相關的特定基因突變或生物標記的能力而得到強調。這種協同效應推動了市場的成長軌跡。

市場區隔

全球原位雜合技術市場可根據產品、技術、應用、最終用戶和地區進行細分。根據產品，市場可進一步分為消耗品、儀器和軟體。根據技術，市場可進一步分為螢光原位雜合技術和顯色原位雜合技術。根據應用，市場可進一步分為癌症診斷、細胞學、傳染病診斷、神經科學和免疫學。根據最終用戶，市場進一步分為醫院和診斷實驗室、學術和研究機構、製藥和生物技術公司以及合約研究組織。

市場參與者

Abbott Laboratories.、F. Hoffmann Roche AG.、Thermo Fisher Scientific Inc.、Danaher Corp.、Agilent Technologies Inc.、Biocare Medical LLC.、Biotechne Corporation.、Qiagen NV、Merck KGAA.、Perkinelmer Inc. 是一些領先的公司全球原位雜合技術市場的參與者。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球原位雜合技術市場也分為以下幾類：

原位雜合技術市場，副產品：

  • 耗材
  • 儀器
  • 軟體

原位雜合技術市場（按技術）：

  • 螢光原位雜合技術
  • 顯色原位雜合技術

原位雜合技術市場，按應用：

  • 癌症診斷
  • 細胞學
  • 傳染病診斷
  • 神經科學
  • 免疫學

原位雜合技術市場，依最終用戶分類：

  • 醫院和診斷實驗室
  • 學術及研究機構
  • 製藥和生物技術公司
  • 合約研究組織

原位雜合技術市場，按地區：

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 南美洲
  • 巴西
  • 阿根廷
  • 哥倫比亞
  • 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

競爭格局

  • 公司概況：全球原位雜合技術市場主要公司的詳細分析。

可用的客製化：

  • 根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球原位雜合技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品（耗材、儀器、軟體）
    • 依技術分類（螢光原位雜合技術與顯色原位雜合技術）
    • 按應用（癌症診斷、細胞學、傳染病診斷、神經科學、免疫學）
    • 按最終用戶（醫院和診斷實驗室、學術和研究機構、製藥和生物技術公司、合約研究組織）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2022)
  • 市場地圖
    • 按產品分類
    • 依技術
    • 按應用
    • 按最終用戶
    • 按地區

第 6 章：北美原位雜合技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品（耗材、儀器、軟體）
    • 依技術分類（螢光與顯色）
    • 按應用（癌症診斷、細胞學、傳染病診斷、神經科學、免疫學）
    • 按最終用戶（醫院和診斷實驗室、學術和研究機構、製藥和生物技術公司、合約研究組織）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲原位雜合技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品（耗材、儀器、軟體）
    • 依技術分類（螢光與顯色）
    • 按應用（癌症診斷、細胞學、傳染病診斷、神經科學、免疫學）
    • 按最終用戶（醫院和診斷實驗室、學術和研究機構、製藥和生物技術公司、合約研究組織）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太原位雜合技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品（耗材、儀器、軟體）
    • 依技術分類（螢光與顯色）
    • 按應用（癌症診斷、細胞學、傳染病診斷、神經科學、免疫學）
    • 按最終用戶（醫院和診斷實驗室、學術和研究機構、製藥和生物技術公司、合約研究組織）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲原位雜合技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品（耗材、儀器、軟體）
    • 依技術分類（螢光與顯色）
    • 按應用（癌症診斷、細胞學、傳染病診斷、神經科學、免疫學）
    • 按最終用戶（醫院和診斷實驗室、學術和研究機構、製藥和生物技術公司、合約研究組織）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲原位雜合技術市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品（耗材、儀器、軟體）
    • 依技術分類（螢光原位雜合技術與顯色原位雜合技術）
    • 按應用（癌症診斷、細胞學、傳染病診斷、神經科學、免疫學）
    • 按最終用戶（醫院和診斷實驗室、學術和研究機構、製藥和生物技術公司、合約研究組織）
    • 按國家/地區
  • MEA：國家分析
    • 南非原位雜合技術
    • 沙烏地阿拉伯原位雜合技術
    • 阿拉伯聯合大公國原位雜合技術

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球原位雜合技術市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • Abbott Laboratories.
    • F. Hoffmann Roche AG.
    • Thermo Fisher Scientific Inc.
    • Danaher Corp.
    • Agilent Technologies Inc.
    • Biocare Medical LLC.
    • Biotechne Corporation.
    • Qiagen NV
    • Merck KGAA.
    • Perkinelmer Inc.

第 16 章：策略建議

簡介目錄
Product Code: 15520

The In Situ Hybridization market was valued at USD 1.53 Billion in 2022, and is poised for remarkable growth with a CAGR Of 7.29% by 2028.. This can be attributed to the heightened awareness surrounding genetic disorders, propelled by the emergence of novel viruses such as COVID-19. Additionally, the escalating demand for molecular diagnostic tools, coupled with the increasing adoption of in situ hybridization technology, is poised to underpin the market's growth in the forthcoming years.

Furthermore, the surging prevalence of genetic disorders within the population is poised to be a pivotal driver of growth during the forecast period. Simultaneously, the strategic initiatives undertaken by various market players, including partnerships, acquisitions, and mergers, aimed at the advancement of in situ hybridization techniques, are expected to exert a substantial positive impact on market growth throughout the forecast period.

Illustrating this trend, the U.S. National Cancer Institute reported a staggering count of 1,898,160 new cancer cases and 608,570 cancer-related fatalities in the United States during 2021. Notably, the World Health Organization's data emphasizes that, by September 2021, a significant 70% of cancer-related deaths were concentrated in low- and middle-income nations.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.53 Billion
Market Size 2028USD 2.34 Billion
CAGR 2023-20287.29%
Fastest Growing SegmentHospitals and Diagnostic Laboratories
Largest MarketNorth America

Growing prevalence of chronic diseases

Chronic ailments wield substantial influence over the trajectory of the global in situ hybridization market. Conditions encompassing cancer, autoimmune diseases, and infectious diseases exhibit a hallmark of genetic aberrations or mutations within cells, lending themselves to detection and visualization through in situ hybridization techniques. The utility of in situ hybridization resides in its ability to identify and pinpoint specific nucleic acid sequences linked to these maladies, thereby enabling timely diagnoses and precision therapies.

The mounting prevalence of chronic diseases propels the demand for in situ hybridization across diagnostic and research applications. In accordance with data from the World Health Organization (WHO), chronic diseases stand as the primary cause of worldwide mortality, accounting for a substantial 71% of all global deaths. Among these, cancer holds significant prominence, contributing significantly to the global chronic disease burden with an estimated 18.1 million new cases and 9.6 million fatalities in 2018. In the realm of cancer, in situ hybridization emerges as a pivotal tool, underpinning diagnosis, prognosis, and treatment. Its prowess in identifying specific genetic aberrations like gene amplification, gene fusion, or gene expression changes guides treatment decisions, tracks disease progression, and predicts therapeutic outcomes.

Beyond cancer, in situ hybridization extends its sphere of influence to encompass other chronic conditions such as infectious diseases and autoimmune disorders. For instance, its application spans the detection of distinct viral or bacterial nucleic acid sequences within infected cells or tissues, facilitating prompt diagnoses and targeted interventions.

Advancements in molecular biology and genetics

The evolution of molecular biology has wielded a substantial influence over the expansion of the global in situ hybridization market. Positioned within the realm of molecular biology, in situ hybridization constitutes a technique facilitating the precise detection and localization of specific nucleic acid sequences within cells or tissues. Recent technological progressions in molecular biology have significantly elevated the sensitivity, specificity, and precision of in situ hybridization assays.

Advancements in the design and synthesis of probes have notably augmented the specificity and sensitivity of in situ hybridization assays. Locked nucleic acid (LNA) probes, for instance, represent a breakthrough development enabling the discernment of low-abundance nucleic acid targets with heightened specificity and sensitivity. Likewise, refinements in labeling and signal amplification techniques have elevated the signal-to-noise ratio of in situ hybridization assays, enabling the discernment of faint signals and low-abundance targets.

The strides in imaging and microscopy have additionally contributed to the augmentation of the in situ hybridization market. Advanced microscopy methods such as confocal microscopy and super-resolution microscopy have substantially heightened the spatial resolution of in situ hybridization assays, thereby facilitating the visualization of subcellular structures and molecular interactions.

Moreover, contemporary molecular biology achievements have paved the way for novel applications of in situ hybridization. For example, fluorescence in situ hybridization (FISH) has evolved to facilitate the simultaneous detection of multiple nucleic acid targets, enabling the analysis of intricate genetic interactions and gene expression patterns. Furthermore, the progress in RNA in situ hybridization techniques has empowered the detection of non-coding RNAs, pivotal players in gene regulation and the genesis of diseases.

Growing demand for personalized medicine

Personalized medicine stands as a pivotal catalyst propelling the expansion of the global in situ hybridization market. This healthcare approach revolves around tailoring treatments to individual patients based on their unique genetic composition, lifestyle, and environmental influences. The pivotal role of in situ hybridization in this paradigm lies in its capacity to unearth specific genetic mutations or biomarkers linked to distinct ailments, thus rendering it a critical tool in personalized medicine's development.

Techniques such as fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) within the in situ hybridization spectrum come to the fore in detecting targeted genetic mutations or alterations tied to diverse conditions, including cancer. These insights equip physicians to curate optimal treatment pathways for each patient, elevating treatment efficacy while mitigating untoward side effects.

The pervasive role of in situ hybridization extends to the realm of companion diagnostics, which function as tests identifying patients most likely to benefit from specific treatments. Leveraged for patient selection in clinical trials, treatment response monitoring, and dosage adjustments, companion diagnostics enhance patient outcomes and mitigate healthcare expenditures.

The trajectory of in situ hybridization's role within personalized medicine is poised for a significant expansion in the foreseeable future. This impetus stems from the growing availability of genetic information and an escalating demand for precision therapies. The concurrent development of innovative in situ hybridization technologies and assays is set to amplify the evolution of the global in situ hybridization market.

Increasing research and development activities

Research and development endeavors exert a pronounced influence over the expansion of the global in situ hybridization market. As an ever-evolving technique, in situ hybridization's growth hinges on the continual creation of novel assays and technologies that extend its application spectrum while enhancing the precision, sensitivity, specificity, and accuracy of its assays. Within the in situ hybridization domain, research and development activities pivot around the refinement of probes, optimization of labeling and signal amplification techniques, and the advancement of imaging and microscopy methodologies.

For instance, the advent of innovative probe technologies like peptide nucleic acid (PNA) probes and locked nucleic acid (LNA) probes has elicited significant enhancements in the sensitivity and specificity of in situ hybridization assays. Progressions in labeling and signal amplification techniques, typified by tyramide signal amplification (TSA), have bolstered the signal-to-noise ratio of these assays, thereby enabling the discernment of faint signals and low-abundance targets. In tandem, the evolution of imaging and microscopy technologies has contributed to the growth trajectory of the in situ hybridization market. High-resolution microscopy modalities such as confocal microscopy and super-resolution microscopy have markedly elevated the spatial resolution of in situ hybridization assays, facilitating the visualization of subcellular structures and molecular interactions.

Furthermore, the purview of research and development initiatives spans the exploration of fresh applications for in situ hybridization. A noteworthy illustration is the technique's employment in studying the distribution and expression patterns of non-coding RNAs. This specific avenue assumes significance due to non-coding RNAs' pivotal role in gene regulation and the progression of diseases.

Rising healthcare expenditure

Healthcare expenditure stands as a pivotal determinant influencing the expansion of the global in situ hybridization market. The surge in demand for in situ hybridization assays and technologies is inherently intertwined with the imperative for precise and dependable diagnostic tools and therapies across a spectrum of maladies, notably cancer. This surge is intrinsically tied to escalating healthcare expenditure, particularly evident in advanced economies, where substantial investments are directed towards research and development activities and the adoption of cutting-edge healthcare technologies. This concerted impetus has engendered the creation of novel and inventive in situ hybridization technologies and assays, characterized by heightened accuracy, sensitivity, specificity, and applicability.

Furthermore, the nexus between healthcare expenditure and the provision of healthcare services, encompassing diagnostic tools and therapies, serves as a linchpin propelling the in-situ hybridization market's growth. Elevated healthcare expenditure has underpinned the emergence of enhanced healthcare infrastructure, encomassning hospitals, clinics, and laboratories, therein augmenting the availability and accessibility of diagnostic tools, including in situ hybridization assays.

In parallel, the escalating healthcare expenditure landscape has galvanized the advance of personalized medicine, which, in turn, buttresses the expansion of the in-situ hybridization market. Personalized medicine underscores treatment customization aligned with patients' genetic composition, lifestyle, and environmental influences. Notably, in situ hybridization's pivotal role in personalized medicine is underscored by its capability to identify specific genetic mutations or biomarkers linked to distinct ailments. This synergy fuels the market's growth trajectory.

Market Segmentation

Global In Situ Hybridization market can be segmented on the basis of product, technology, application, end user and region. Based on product, the market can be further divided into consumables, instruments, and software. Based on technology, the market can be further divided into fluorescent in situ hybridization v/s chromogenic in situ hybridization. Based on application, the market can be further divided into cancer diagnostics, cytology, infectious diseases diagnostics, neuroscience, and immunology. Based on end user, the market is further divided into hospitals and diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations.

Market Players

Abbott Laboratories., F. Hoffmann Roche AG., Thermo Fisher Scientific Inc., Danaher Corp., Agilent Technologies Inc., Biocare Medical LLC., Biotechne Corporation., Qiagen N.V, Merck KGAA., Perkinelmer Inc. are some of the leading players operating in the global In Situ Hybridization market.

Report Scope:

In this report, Global In Situ Hybridization market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In Situ Hybridization Market, By Product:

  • Consumables
  • Instruments
  • Software

In Situ Hybridization Market, By Technology:

  • Fluorescent in situ hybridization
  • Chromogenic in situ hybridization

In Situ Hybridization Market, By Application:

  • Cancer Diagnostics
  • Cytology
  • Infectious diseases diagnostics
  • Neuroscience
  • Immunology

In Situ Hybridization Market, By End User:

  • Hospitals and Diagnostic laboratories
  • Academic & Research institutes
  • Pharmaceutical & Biotechnology companies
  • Contract research organizations

In Situ Hybridization Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global In Situ Hybridization Market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In Situ Hybridization Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumables, Instruments, Software)
    • 5.2.2. By Technology (Fluorescent in situ hybridization v/s Chromogenic in situ hybridization)
    • 5.2.3. By Application (Cancer Diagnostics, Cytology, Infectious diseases diagnostics, Neuroscience, Immunology)
    • 5.2.4. By End user (Hospitals and Diagnostic laboratories, Academic & Research institutes, Pharmaceutical & Biotechnology companies, Contract research organizations)
    • 5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.6. By Company (2022)
  • 5.3. Market Map
    • 5.3.1 By Product
    • 5.3.2 By Technology
    • 5.3.3 By Application
    • 5.3.4 By End User
    • 5.3.5 By Region

6. North America In Situ Hybridization Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product (Consumables, Instruments, Software)
    • 6.2.2. By Technology (Fluorescent in situ hybridization v/s Chromogenic in situ hybridization)
    • 6.2.3. By Application (Cancer Diagnostics, Cytology, Infectious diseases diagnostics, Neuroscience, Immunology)
    • 6.2.4. By End user (Hospitals and Diagnostic laboratories, Academic & Research institutes, Pharmaceutical & Biotechnology companies, Contract research organizations)
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States In Situ Hybridization Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada In Situ Hybridization Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico In Situ Hybridization Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe In Situ Hybridization Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product (Consumables, Instruments, Software)
    • 7.2.2. By Technology (Fluorescent in situ hybridization v/s Chromogenic in situ hybridization)
    • 7.2.3. By Application (Cancer Diagnostics, Cytology, Infectious diseases diagnostics, Neuroscience, Immunology)
    • 7.2.4. By End user (Hospitals and Diagnostic laboratories, Academic & Research institutes, Pharmaceutical & Biotechnology companies, Contract research organizations)
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France In Situ Hybridization Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany In Situ Hybridization Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom In Situ Hybridization Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy In Situ Hybridization Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain In Situ Hybridization Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific In Situ Hybridization Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product (Consumables, Instruments, Software)
    • 8.2.2. By Technology (Fluorescent in situ hybridization v/s Chromogenic in situ hybridization)
    • 8.2.3. By Application (Cancer Diagnostics, Cytology, Infectious diseases diagnostics, Neuroscience, Immunology)
    • 8.2.4. By End user (Hospitals and Diagnostic laboratories, Academic & Research institutes, Pharmaceutical & Biotechnology companies, Contract research organizations)
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China In Situ Hybridization Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India In Situ Hybridization Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan In Situ Hybridization Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea In Situ Hybridization Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia In Situ Hybridization Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America In Situ Hybridization Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product (Consumables, Instruments, Software)
    • 9.2.2. By Technology (Fluorescent in situ hybridization v/s Chromogenic in situ hybridization)
    • 9.2.3. By Application (Cancer Diagnostics, Cytology, Infectious diseases diagnostics, Neuroscience, Immunology)
    • 9.2.4. By End user (Hospitals and Diagnostic laboratories, Academic & Research institutes, Pharmaceutical & Biotechnology companies, Contract research organizations)
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil In Situ Hybridization Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina In Situ Hybridization Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia In Situ Hybridization Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa In Situ Hybridization Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product (Consumables, Instruments, Software)
    • 10.2.2. By Technology (Fluorescent in situ hybridization v/s Chromogenic in situ hybridization)
    • 10.2.3. By Application (Cancer Diagnostics, Cytology, Infectious diseases diagnostics, Neuroscience, Immunology)
    • 10.2.4. By End user (Hospitals and Diagnostic laboratories, Academic & Research institutes, Pharmaceutical & Biotechnology companies, Contract research organizations)
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa In Situ Hybridization Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia In Situ Hybridization Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE In Situ Hybridization Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global In Situ Hybridization Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1 Abbott Laboratories.
    • 15.6.2 F. Hoffmann Roche AG.
    • 15.6.3 Thermo Fisher Scientific Inc.
    • 15.6.4 Danaher Corp.
    • 15.6.5 Agilent Technologies Inc.
    • 15.6.6 Biocare Medical LLC.
    • 15.6.7 Biotechne Corporation.
    • 15.6.8 Qiagen N.V
    • 15.6.9 Merck KGAA.
    • 15.6.10 Perkinelmer Inc.

16. Strategic Recommendations